Prime Medicine, Inc Common Stock

Yahoo Finance • 26 days ago

Prime Drink Group Provides Bi-Weekly MCTO Status Report

MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 15, and August 29, 2025, the Company voluntarily applied for an... Full story

Yahoo Finance • 26 days ago

Groupe Prime Drink fournit un rapport bihebdomadaire sur le statut du MCTO

MONTRÉAL, 12 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce que, conformément à ses communiqués du 30 juillet, du 15 août et du 29 août 2025, la Société a volontairement déposé... Full story

Yahoo Finance • last month

Prime Drink Group Terminates Rights Offering and Announces Private Placement

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has terminated its previously disclosed rights offering and that it is proceeding with a non-brokered private p... Full story

Yahoo Finance • last month

Groupe Prime Drink met fin au placement de droits et annonce un placement privé

MONTRÉAL, 04 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce qu’elle a mis fin à son placement de droits précédemment divulgué et qu’elle procédera à un placement privé d'unités... Full story

Yahoo Finance • 2 months ago

Prime Drink Group receives extension for annual financial filings

MONTREAL - Prime Drink Group Corp. (CSE:PRME), a beverage company with a market capitalization of $477.21 million, has received an extension to file its annual financial statements for the period ended March 31, 2025, the company announced... Full story

Yahoo Finance • 2 months ago

Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company at the forefront of gene editing technology, focusing on developing treatments for serious genetic diseases. With a market capitalization of $499.5 million and a beta of 2.41, t... Full story

Yahoo Finance • 2 months ago

Guggenheim cuts Prime Medicine stock price target to $5 from $18

Investing.com - Guggenheim lowered its price target on Prime Medicine (NASDAQ:PRME) to $5.00 from $18.00 on Wednesday, while maintaining a Buy rating on the gene editing company’s stock. Currently trading at $3.46, the stock sits below Inv... Full story

Yahoo Finance • 2 months ago

Prime Medicine stock price target lowered to $10 at Chardan on cash update

Investing.com - Chardan Capital Markets lowered its price target on Prime Medicine (NASDAQ:PRME) to $10.00 from $12.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter results. According to InvestingPro... Full story

Yahoo Finance • 2 months ago

Arch venture fund XII buys Prime Medicine shares worth $9.99m

Arch Venture Fund XII, L.P. purchased 3,030,300 shares of Prime Medicine , Inc. (NASDAQ:PRME) on August 1, 2025, at a price of $3.30 per share, in a transaction totaling $9,999,990. The stock currently trades at $4.04, representing a 22%... Full story

Yahoo Finance • 2 months ago

Prime Medicine stock falls after pricing public offering

Investing.com -- Prime Medicine Inc (NASDAQ:PRME) stock tumbled 12.5% premarket after the biotechnology company announced the pricing of a public offering of 38 million shares at $3.30 per share. The offering, which is expected to close... Full story

Yahoo Finance • 2 months ago

Prime Medicine slides after pricing $125.4M stock offering

* Prime Medicine (NASDAQ:PRME [https://seekingalpha.com/symbol/PRME]) has priced its public offering of 38 million shares at $3.30 each, aiming to raise about $125.4 million before expenses. * The company has also given underwriters a... Full story

Yahoo Finance • 2 months ago

Prime Medicine Announces Pricing of Public Offering

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an... Full story

Yahoo Finance • 2 months ago

Prime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial Statements

MONTREAL, July 30, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that, pursuant to a notice of variation dated July 29, 2025 (the “Notice of Variation”), it has extended the expiry date... Full story

Yahoo Finance • 2 months ago

Groupe Prime Drink prolonge la date d'expiration de son placement de droits et annonce un retard dans le dépôt de ses états financiers annuels

MONTRÉAL, 30 juill. 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce que, conformément à un avis de modification daté du 29 juillet 2025 (l’« avis de modification »), elle a prolongé la... Full story

Yahoo Finance • 2 months ago

Prime Medicine announces public stock offering; shares down 11.5%

* Prime Medicine (NASDAQ:PRME [https://seekingalpha.com/symbol/PRME]) has commenced an underwritten public offering of its common stock. * The company plans to grant underwriters a 30-day option to purchase up to 15% additional shares.... Full story

Yahoo Finance • 2 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has comme... Full story

Yahoo Finance • 2 months ago

Prime Medicine's SWOT analysis: gene editing firm faces cash crunch amid strategic shift

Prime Medicine , Inc. (NASDAQ:PRME), a biotechnology company with a market capitalization of $552 million at the forefront of gene editing technology, finds itself at a critical juncture as it navigates a strategic pivot and financial chal... Full story

Yahoo Finance • 3 months ago

Cystic Fibrosis Foundation expands funding for Prime Medicine

CAMBRIDGE, Mass. - Prime Medicine, Inc. (NASDAQ:PRME), a $562 million market cap biotechnology company whose stock has surged nearly 47% year-to-date, announced Wednesday that the Cystic Fibrosis Foundation has committed up to $24 million... Full story

Yahoo Finance • 3 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Mul... Full story

Yahoo Finance • 3 months ago

Prime Medicine chief scientific officer to depart, will serve as consultant

Prime Medicine , Inc. (NASDAQ:PRME), a biotechnology company with a market capitalization of $630 million, announced Monday that Jeremy Duffield, M.D., Ph.D., FRCP will step down from his position as Chief Scientific Officer, effective Tue... Full story